ATE546151T1 - Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung - Google Patents

Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung

Info

Publication number
ATE546151T1
ATE546151T1 AT04726480T AT04726480T ATE546151T1 AT E546151 T1 ATE546151 T1 AT E546151T1 AT 04726480 T AT04726480 T AT 04726480T AT 04726480 T AT04726480 T AT 04726480T AT E546151 T1 ATE546151 T1 AT E546151T1
Authority
AT
Austria
Prior art keywords
suffering
sars
mucosa
believed
acute respiratory
Prior art date
Application number
AT04726480T
Other languages
English (en)
Inventor
Nisar Khan
Robbert Benner
Gert Wensvoort
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03076030A external-priority patent/EP1466613A1/de
Priority claimed from US10/409,671 external-priority patent/US20030220261A1/en
Priority claimed from EP03076023A external-priority patent/EP1466612A1/de
Priority claimed from EP03076022A external-priority patent/EP1466611A1/de
Priority claimed from CNB031312276A external-priority patent/CN1310674C/zh
Application filed by Biotempt Bv filed Critical Biotempt Bv
Application granted granted Critical
Publication of ATE546151T1 publication Critical patent/ATE546151T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT04726480T 2003-04-08 2004-04-08 Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung ATE546151T1 (de)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP03076030A EP1466613A1 (de) 2003-04-08 2003-04-08 HCG-Fragmente enthaltene Zusammensetzungen zur mukosalen und oralen Anwendung
EP03076027 2003-04-08
US10/409,671 US20030220261A1 (en) 2001-12-21 2003-04-08 Treatment of iatrogenic disease
EP03076023A EP1466612A1 (de) 2003-04-08 2003-04-08 Behandlung von Entzündung und Sepsis mit hCG-Peptidderivate
EP03076029 2003-04-08
EP03076026 2003-04-08
EP03076025 2003-04-08
EP03076021 2003-04-08
EP03076028 2003-04-08
EP03076022A EP1466611A1 (de) 2003-04-08 2003-04-08 Verwendung von HCG Peptidderivate zur Behandlung von iatrogene Krankheiten
EP03076024 2003-04-08
CNB031312276A CN1310674C (zh) 2003-04-30 2003-04-30 治疗重症急性呼吸综合征的药物组合物
PCT/EP2004/003747 WO2004093897A1 (en) 2003-04-08 2004-04-08 Compositions for mucosal and oral administration comprising hcg fragments

Publications (1)

Publication Number Publication Date
ATE546151T1 true ATE546151T1 (de) 2012-03-15

Family

ID=33314656

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04726480T ATE546151T1 (de) 2003-04-08 2004-04-08 Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung

Country Status (8)

Country Link
EP (1) EP1615655B1 (de)
JP (1) JP4848267B2 (de)
KR (1) KR101184833B1 (de)
AT (1) ATE546151T1 (de)
AU (1) AU2004231300A1 (de)
CA (1) CA2520655A1 (de)
NZ (1) NZ542791A (de)
WO (2) WO2005046569A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
WO2007097624A1 (en) * 2006-02-21 2007-08-30 Biotempt B.V. Pharmaceutical compositions for the treatment of influenza infections
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX355683B (es) 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
EP2437772B1 (de) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunregulierende peptide und verwendungsverfahren dafür
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
EP3307326B9 (de) 2015-06-15 2021-02-24 Angiochem Inc. Verfahren zur behandlung von leptomeningealer karzinomatose
JP7093559B2 (ja) 2016-04-12 2022-06-30 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
FR3087338B1 (fr) 2018-10-22 2020-10-09 Amadeite Extrait d'algues pour son utilisation pour le traitement ou la prevention de l'immunosuppression post-traumatique
MX2022012506A (es) * 2020-04-06 2023-01-16 Biotempt Bv Métodos y medios para modificar la hemodinámica en infecciones.
AU2021354766A1 (en) * 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
US20240173375A1 (en) 2021-03-02 2024-05-30 Biotempt B.V. Chemotactic autophagy-inhibiting peptide, compositions and methods related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (de) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide

Also Published As

Publication number Publication date
KR101184833B1 (ko) 2012-09-20
JP2007525426A (ja) 2007-09-06
CA2520655A1 (en) 2004-11-04
AU2004231300A1 (en) 2004-11-04
JP4848267B2 (ja) 2011-12-28
EP1615655B1 (de) 2012-02-22
KR20060017493A (ko) 2006-02-23
WO2005046569A2 (en) 2005-05-26
EP1615655A1 (de) 2006-01-18
NZ542791A (en) 2008-04-30
WO2005046569A3 (en) 2005-12-22
WO2004093897A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
ATE546151T1 (de) Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE50311502D1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
DE602004017174D1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
MY138708A (en) Biaryloxymethylarenecarboxylic acids
IL171972A0 (en) Compositions and methods for treatment of severe acute respiratory syndrome(sars)
ATE392208T1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
WO2005018605A3 (en) Novel formulation of ropinirole
BRPI0411085A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
ATE361076T1 (de) Kombination von loteprednoletabonat und dfho zur behandlung von atemwegserkrankungen, allergischen erkrankungen, asthma und copd
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
SE0401631L (sv) Ny sammansättning
DE602005019416D1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
WO2005002500A3 (en) Inhibitors of coronavirus
DE60321953D1 (de) Neue synergistische zusammensetzung enthaltend roflumilast und formoterol
WO2008043570A8 (en) Interferon type i supporting compounds
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
NO20063413L (no) Nye CC-kjemokinlindrende proteiner
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren